Penn Medicine Provider
Dermatology
Nicholas Kian Mollanazar, MD, MBA
he/him/his
4.5
(1378)
Accepting new patients
Sees patients age 18 and up
Penn Dermatology Perelman
Schedule onlineCall 215-662-2737

About me

  • Co-Chair, Electronic Medical Record Governance, Department of Dermatology
  • Director, Dermatology Patient Access
  • Applied Informatics Specialist, Dermatology
  • Assistant Professor of Clinical Dermatology

Education and training

  • Medical School: Temple University
  • Residency: Pennsylvania Hospital
  • Residency: Temple University Hospital

What my patients think about me

Average Rating
4.5

1378 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

May 2025
5.0
5.0
overall great
April 2025
5.0
5.0
dr. was easy to get along with
April 2025
4.0
4.0
visit felt extremely rushed
April 2025
5.0
5.0
he gave me new medication that worked. i've been living 50 years with this.

Insurance accepted

My Locations

Learn about location

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Mollanazar is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Kwatra SG, Yosipovitch G, Mollanazar N, Stander S, Kim BS, Hong HC, Msihid J, Bansal A, O'Malley TJ, Bahloul D, Thomas RB Dupilumab Improves Multiple Factors Impacting Quaility of Life in Adults With Prurigo Nodulras (LIBERTY-PN PRIME and PRIME2) , CDA Annual Conference 2023: 2023

Florez A, Yosipovitch G, Kwatra SG, Mollanazar N, Stander S Satoh T, Laws E, Mannent LP, Mortensen E, Maloney J, Shi G, Bansal, Martincova R Dupilumab Significantly Improves Itch and Skin Lesions in Patients With Prurigo Nodulras: Pooled Results From Two Phase 3 Trails (LIBERTY-PN PRIME and PRIME 2) , Academia Espnola de Dermatologia y Venereologia (AEDV): 2023

Yosipovitch G, Mollanazar N, Stander S, Kwatra SG, Kim BS, Laws E, Mannent LP, Amin N, Akinlade, Staudinger H, Patel N, Yancopoulos GD, Weinreich DM, Wang S, Shi G, Bansal A, O'Malley JT Dupilumab in adult patients with prurigo nodularis: results from two randomized phase 3 trails , Nature Medicine: 2023

Sow, Y., Wachuku, C., Barrera, T., Jackson, T., Ayoade, K. O., Taylor, S., & Mollanazar, N Palmer and Plantar Erythema: An Initial Presentation of Undifferentiated Connective Tissue Disease , JAAD Case Reports, 35: 2023,94-97

Wachuku, C., Barrera, T., Jackson, T., Sow, Y., Mollanazar, N., & Taylor, S.C Upadacitinib, after failure with Dupilumab, as a treatment for chronic pruritus secondary to Polycythemia Vera , JAAD Case Reports, 35: 2023,87-89

Kwatra SG, Yosipovitch G, Mollanazar N, Stander S, Kim BS, Msihid J, Bansal A, O'Malley TJ, Bahloul D, Thomas RB Dupilumab Improves Multiple Factors Impacting Quaility of Life in Adults With Prurigo Nodulras (LIBERTY-PN PRIME and PRIME2) , AAD Association Annual Meeting: 2023

Kwatra SG, Yosipovitch G, Mollanazar N, Stander S, Kim BS, Msihid J, Bansal A, O'Malley TJ, Bahloul D, Thomas RB Dupilumab Improves Multiple Factors Impacting Quaility of Life in Adults With Prurigo Nodulras (LIBERTY-PN PRIME and PRIME2) , 81th Annual Meeting of the American Academy of Dermatology: 2023

Yosipovitch G, Mollanazar N, Stander S, Kwatra SG, Kim BS, Laws E, Mannent LP, Amin N, Akinlade B, Wang S, Shi G, Patel K, Bansal A, O'Malley TJ Dupilumab Significantly Improves Itch and Skin Lesions in Patients With Prurigo Nodulras: Pooled Results From a 2nd Phase 3 Trail (LIBERTY-PN PRIME) , Hawaii Dermatology Seminar - 45th Annual : 2023

Yosipovitch G, Kwatra SG, Mollanazar N, Stander S Satoh T, Laws E, Mannent LP, Mortensen E, Maloney J, Shi G, Bansal A, Martincova R Dupilumab Significantly Improves Itch and Skin Lesions in Patients With Prurigo Nodulras: Pooled Results From a 2nd Phase 3 Trails (LIBERTY-PN PRIME and PRIME2) , 4th San Diego Dermatology Symposium: 2023

Yosipovitch G, Kwatra SG, Mollanazar N, Stander S Satoh T, Laws E, Mannent LP, Mortensen E, Maloney J, Shi G, Bansal, Martincova R Dupilumab Significantly Improves Itch and Skin Lesions in Patients With Prurigo Nodulras: Pooled Results From Two Phase 3 Trails (LIBERTY-PN PRIME and PRIME 2) , Maui Derm Hawaii: 2023

View all publications